EntreMed appoints Franklin C. Salisbury, Jr., President of NFCR, to Board of Directors
1 hour ago
ROCKVILLE, Md., June 3, 2014 /PRNewswire/ -- EntreMed, Inc. (ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that Franklin C. Salisbury, Jr. has joined the Company's Board of Directors.
wonder why the announcement now..why today when we have a poster this morning... it may mean nothing but it alitte strange to me.. Mr. Salisbury comes in before all the news is out??????????jmo
so i will own what? regi shares. thanks
I couldn't agree more. A 11 patient trial is more like a bridge game, and to show 27% of the 11 patients seems more like making the numbers better than they are. So if the trail had 2 pateints and one responded wouldnt that be 50%?. After all this time still no meat and potatoes news. Share holders have no real solid news. All we have is alot of carrot and stick news. New member, some more money, new trials, alittle nice office in China. All "BUNK" news.. I know it takes time but 15 years and a billion or so bucks. Come on already gives us shares holders something..For God's sake I own a bubble gum company that doing better.. Not a fair comparison, No but still frustrating as he.. ll .
18,000 share so far today.................... is that now considered heavy volume for this stock.. it's triple from days ago.........................................................
Under the amendment to the 2011 Plan, (i) the number of shares of Common Stock reserved for issuance increased from 4,230,000 to 5,730,000.The Company's executive officers and directors are eligible to receive awards under the 2011 Plan in accordance with the terms and conditions set forth therein. A copy of the 2011 Plan, as amended, was filed with the Securities and Exchange Commission on April 21, 2014 as Appendix A to the Company's Definitive Proxy Statement on Schedule 14A (the "Proxy Statement") for the Annual Meeting and is incorporated herein by reference. (REWARDS? REALLY )
Hope for MannKind
Returning to land, MannKind shareholders got some good news today, when RBC Capital announced it is initiating coverage of the company with an "outperform" rating in response to reports that MannKind is only six to eight weeks away from announcing a partnership to market its breakthrough Afrezza insulin inhaler.
"Multiple potential partners" are said to be courting MannKind on this deal, despite the FDA not having yet given final approval for the product. And RBC thinks this news could help drive MannKind shares up as much as 60%, to a new target price of $16 a share within a year.